·计算药物发现 ·内部研究
Simulations Plus: A Credible Drug-Modeling Specialist, Now Priced as a Near-Cash Deal Stock
Simulations Plus builds scientifically trusted drug-development modeling software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym), but its revenue mix has drifted toward lower-margin services since the 2024 Pro-ficiency acquisition, which pulled FY2025 gross margin to 58% and triggered a $77.2m impairment. On 2026-06-26 the equity trades as a near-cash event security: Altaris' agreed $18.50-per-share takeout caps upside just above the $18.14 close, while a broken deal would reopen real downside. Rating Avoid: a thin-spread cash-deal security whose unresolved software-mix question still sits underneath the transaction.
Avoid